Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wheelchair group files suit against CMS

This article was originally published in The Gray Sheet

Executive Summary

:The Power Mobility Coalition, a group of industry suppliers and manufacturers, filed a temporary injunction against CMS Oct. 13 in an attempt to stop the agency from implementing its interim final rule on power mobility devices. On Oct. 14, CMS announced it was postponing local coverage determinations on new codes for wheelchair reimbursement. The agency did not postpone implementation of the rule, which becomes effective Oct. 25. The coalition has said the rule would establish a method of prescription that is more subjective and prone to error than the current certificate of medical necessity-based system (1"The Gray Sheet" Sept. 19, 2005, p. 9)...

You may also be interested in...



Power Wheelchair Suppliers Spar With CMS Over New Regs

Suppliers of power mobility equipment say CMS' new interim final rule on the devices creates a system that is more complicated than the one it replaces and should not be implemented until next April

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel